[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502465":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":43,"locations":53,"responsibleParty":138,"collaborators":141,"id":148,"slug":149,"hasResults":150,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":150,"sex":155,"minAge":156,"maxAge":25,"enrollmentInfo":157,"targetDuration":25,"studyType":160,"phases":161,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":56,"whyStopped":25,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},{"fullName":5,"class":6},"University of Washington","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide","EXPERIMENTAL","Semaglutide group from 0.25mg to 1.0mg",[13],"Drug: Semaglutide",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo group",[19],"Other: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","1.0 mg",[9],null,{"type":6,"name":15,"description":15,"armGroupLabels":27,"otherNames":25},[15],[29,32,35,38,40],{"name":30,"affiliation":5,"role":31},"Ian de Boer, MD, MS","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":34,"role":31},"Jessica Kendrick, MD","University of Colorado Anschutz Medical Campus and Children's Hospital Colorado",{"name":36,"affiliation":37,"role":31},"David Cherney, PhD, MD","University of Toronto",{"name":39,"affiliation":5,"role":31},"Irl Hirsch, MD",{"name":41,"affiliation":42,"role":31},"Katherine Tuttle, MD","Providence Healthcare",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":25,"email":48},"Ernest Ayers, MSPH","CONTACT","206-685-1423","ayerse@uw.edu",{"name":50,"role":46,"phone":51,"phoneExt":25,"email":52},"Leila Zelnick, PhD","206-543-2981","lzelnicke@uw.edu",[54,77,96,115],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"University of Colorado Anschutz Medical Campus","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-104.83192,39.72943,{"lat":66,"lon":65},[69,73,76],{"name":70,"role":46,"phone":71,"phoneExt":25,"email":72},"Madeline Harbour, BA","720-689-4751","madeline.harbour@childrenscolorado.org",{"name":74,"role":46,"phone":71,"phoneExt":25,"email":75},"Carissa Birznieks, BS","carissa.birznieks@cuanschutz.edu",{"name":33,"role":31,"phone":25,"phoneExt":25,"email":25},{"facility":5,"status":56,"city":78,"state":79,"zip":80,"country":60,"countryCode":61,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Seattle","Washington","98104",{"type":63,"coordinates":82},[83,84],-122.33207,47.60621,{"lat":84,"lon":83},[87,91,95],{"name":88,"role":46,"phone":89,"phoneExt":25,"email":90},"Jesica D Baran","425-624-7899","jbaran@uw.edu",{"name":92,"role":46,"phone":93,"phoneExt":25,"email":94},"Dori Khakpour, RDN CDE","206-945-4954","dorik@uw.edu",{"name":39,"role":31,"phone":25,"phoneExt":25,"email":25},{"facility":97,"status":56,"city":98,"state":79,"zip":99,"country":60,"countryCode":61,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Providence Sacred Heart Medical Center","Spokane","99204",{"type":63,"coordinates":101},[102,103],-117.42908,47.65966,{"lat":103,"lon":102},[106,110,114],{"name":107,"role":46,"phone":108,"phoneExt":25,"email":109},"Nicole Maser, MSN RN","509-474-5313","nicole.maser@providence.org",{"name":111,"role":46,"phone":112,"phoneExt":25,"email":113},"Susan Hood, PhD CCRC","509-474-4224","susan.hood@providence.org",{"name":41,"role":31,"phone":25,"phoneExt":25,"email":25},{"facility":116,"status":56,"city":117,"state":118,"zip":119,"country":120,"countryCode":121,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Toronto General Hospital, University Health Network","Toronto","Ontario","M5G2N2","Canada","CA",{"type":63,"coordinates":123},[124,125],-79.39864,43.70643,{"lat":125,"lon":124},[128,133,136],{"name":129,"role":46,"phone":130,"phoneExt":131,"email":132},"Vesta Lai","416-340-4800","8508","vesta.lai@uhn.ca",{"name":134,"role":46,"phone":130,"phoneExt":131,"email":135},"Cheng Xu","cheng.xu@uhn.ca",{"name":137,"role":31,"phone":25,"phoneExt":25,"email":25},"David Cherney, MD CM PhD",{"type":31,"investigatorFullName":139,"investigatorTitle":140,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Ian deBoer","Professor, School of Medicine",[142,144,146,147],{"name":143,"class":6},"Juvenile Diabetes Research Foundation",{"name":145,"class":6},"University of Colorado, Denver",{"name":42,"class":6},{"name":37,"class":6},"100502465","phase-2-trial-of-semaglutide-for-diabetic-kidney-disease-in-type-1-diabetes-100502465",false,"NCT05822609","Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes","RT1D","Inclusion Criteria:\n\n* Adults (≥18 years) with type 1 diabetes\n* Diabetes duration of ≥5 years\n* Persistent urine albumin-to-creatinine ratio (UACR) ≥ 30 mg\u002Fg, on the most recent two measurements within the prior 3 years\n* Estimated glomerular filtration rate ≥ 20 mL\u002Fmin\u002F1.73m2\n* Stable doses of drugs altering blood pressure (e.g., Angiotensin-converting enzyme inhibitor) required for at least 4 weeks prior to randomization, and requested for the duration of the trial\n* Stable doses of lipid-lowering medications required for at least 4 weeks prior to randomization, and requested for the duration of the trial\n* Adequate contraceptive method for females of child-bearing potential\n\nExclusion Criteria:\n\n* HbA1c \\>9%, recent diabetic ketoacidosis, hyperosmolar hyperglycemic state or severe illness requiring hospitalization in past 30 days\n* Other causes of diabetes mellitus, including type 2 diabetes and maturity-onset diabetes of the young (MODY)\n* Chronic kidney disease unrelated to diabetes\n* Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or thyroid nodule palpated by endocrinologist at screening\n* Personal history of pancreatitis\n* Current\u002Fplanned pregnancy or nursing\n* Uncontrolled thyroid disease or hypertension (Systolic blood pressure \\[SBP\\] ≥ 160 mm Hg or diastolic blood pressure \\[DBP\\] ≥ 100 mm Hg despite treatment)\n* Proliferative retinopathy with treatment in the past 6 months\n* Uncontrolled or potentially unstable diabetic retinopathy or maculopathy, verified by fundus examination with pupil dilation unless performed using a digital fundus photography camera specified for non-dilated examination\n* More than 2 severe hypoglycemic episodes (requiring glucagon and\u002For assistance from another person) in the past 6 months\n* Frequent hypoglycemia during the last two weeks of the study run-in phase (time below range \\[\\\u003C70 mg\u002FdL\\] ≥4%)\n* Pramlintide and the use of glycemia treatments not approved for type 1 diabetes by the FDA, e.g., metformin, SGT-2 inhibitor, GLP-1 receptor agonist, closed loop insulin delivery using unapproved algorithms\n* Significant systemic conditions or treatment such as cancer or immunomodulators\n* Known liver disease other than non-alcoholic fatty liver disease (NAFLD) or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>100 IU\u002FL, history of severe gastrointestinal disease (e.g., gastroparesis) or gallstones\n* Body mass index \\\u003C20 kg\u002Fm2\n* Known or suspected allergy\u002Fsensitivity to semaglutide or its excipients\n* Pregnant, breast feeding, or the intention of becoming pregnant\n* The receipt of any investigational drug within 3 months prior to this trial\n* Previously randomized in this trial","ALL","18 Years",{"count":158,"type":159},60,"ESTIMATED","INTERVENTIONAL",[162],"PHASE2","The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes. The secondary objective is to determine the effects of semaglutide on change in kidney parameters (including kidney oxygenation and function) measured by MRI from baseline to 26 weeks in type 1 diabetes. Other objectives are to determine the glycemic effects and safety of semaglutide in type 1 diabetes.",[165,166],"Diabetic Kidney Disease","Type 1 Diabetes",[168],"Glucagon-like peptide-1 receptor agonist","2026-05-29",{"date":171,"type":172},"2026-06-02","ACTUAL",{"date":174,"type":172},"2024-04-05",{"date":176,"type":159},"2027-12",{"name":5,"class":6},4]